Detalhe da pesquisa
1.
An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
Am J Kidney Dis
; 74(1): 56-72, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30851964
2.
Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis.
J Immunol
; 199(3): 1021-1040, 2017 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28652401
3.
Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome.
J Am Soc Nephrol
; 29(1): 240-249, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28993505
4.
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.
Blood
; 124(11): 1715-26, 2014 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25037630
5.
A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.
J Immunol
; 193(11): 5567-75, 2014 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25355917
6.
A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation.
J Am Soc Nephrol
; 26(1): 209-19, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24904082
7.
A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.
Pediatr Nephrol
; 30(6): 1039-42, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25752761
8.
Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity.
Front Immunol
; 15: 1383123, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38799460
9.
Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
J Immunol
; 187(1): 172-80, 2011 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21642543
10.
An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome.
Front Immunol
; 14: 1112257, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36845135
11.
SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation.
Front Immunol
; 13: 827146, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35320941
12.
Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19.
Front Pharmacol
; 13: 842473, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35295324
13.
C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19.
Blood Adv
; 6(3): 866-881, 2022 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34852172
14.
Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
Front Immunol
; 12: 711915, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34276706
15.
Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study.
PLoS One
; 16(12): e0261113, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34928990
16.
Molecular Studies and an ex vivo Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant.
Front Med (Lausanne)
; 7: 579418, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33224962
17.
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
Thromb Haemost
; 101(2): 233-8, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19190804
18.
ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes.
Diabetes
; 67(10): 2069-2083, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29976618
19.
In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura.
Thromb Haemost
; 96(4): 454-64, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17003922
20.
Complement activation and effect of eculizumab in scleroderma renal crisis.
Medicine (Baltimore)
; 95(30): e4459, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27472742